Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts

As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much damage can Washington really do to Big Pharma’s bottom line?The answer for ETF investors may be far less alarming than the political noise suggests.Medicaid Math Cools The Fear FactorThe current generation of deals, which is likely to involve AbbVie (NYSE:ABBV) , Merck & Co Inc (NYSE:MRK) , Bristol-Myers Squibb ...